A ‘Game-Changing’ Gene Therapy: This Biotech May Bring First Huntington’s Treatment

A gene therapy just did what no drug has managed in decades: slowing Huntington’s disease by 75%.

Experts are calling the results game-changing, and traders are betting this could lead to the first approved treatment for the condition.

With equity in the brand and athletes pushing viral drops, the University of Alabama is betting on more than just football wins.

This company built the tech-and got the team on board.

Check out the brand changing how college sports profits

U.S. stocks pulled back for a second day with tech and AI stocks dragging and Powell’s warning on inflation tempering Fed cut optimism.

Walmart (NYSE: WMT) just pulled off another sales win with U.S. comparable sales up 4.6% and 7,400 new price rollbacks.

Stores are packed, carts are full, and shoppers are clearly feeling the love.

On the surface, it looks like a dream quarter. But then comes the surprise guest: $400 million in liability costs.

Slips, trips, and product mishaps may be fewer, but each one is hitting the wallet a lot harder.

Profits Take a Spill

Here’s the rub: while sales raced ahead, profits barely inched up. That liability bill ate into the margin investors actually care about.

You can celebrate the traffic boom, but if accidents cost more than the extra groceries sold, Wall Street won’t clap for long.

And it’s not just Walmart. Retailers across the board, Best Buy, Dollar Tree, and Dollar General, are all feeling the sting of pricier claims.

Turns out inflation didn’t just jack up milk and eggs, it jacked up lawsuits too.

The Real Game

For you, this is the reminder that sales headlines don’t pay your portfolio, but profits do. Walmart can keep rolling back prices for shoppers, but it still has to roll forward cash for claims.

Sometimes the biggest competitor isn’t Amazon… It’s a banana peel in aisle five.

Oracle (NYSE: ORCL) just dialed up Wall Street for a $15 billion bond sale. Not your usual five-year paper either — this one’s split into seven slices, including a rare 40-year bond.

That’s Larry Ellison telling the market, “Strap in, this is long-haul money.”

Why? Because Oracle is racing to catch Amazon, Microsoft, and Google in the cloud. Those fresh AI deals with OpenAI and Meta sound glamorous, but they also torch cash faster than a server farm at full tilt.

The Debt Diet Isn’t Light

Here’s the kicker: Oracle’s cash flow turned negative this year, the first time since 1992. Analysts don’t expect it back in the black until 2029.

That makes you sweat if you’re holding the stock.

But if you’re buying the bonds? You’re basically betting Oracle stays investment-grade while it builds the skeleton of AI’s future.

Even with $95 billion already on the books, ratings agencies still consider it safe, not at risk of sinking.

What You Should See Here

This isn’t just a debt raise, it’s a statement: Oracle is willing to mortgage tomorrow to stake its AI claim today. You have to decide — is that reckless or brilliant?

If you believe in the long game, those billions look less like a gamble and more like empire bricks. Sometimes, the biggest flex is writing a check you’ll be paying back in 2065.

The biggest trades aren’t about hype. They’re about math.

Here’s the math today:

BNB fuels 290 million Binance users daily. It reduces fees, powers DeFi, anchors stablecoin activity, and is burned quarterly. And unlike the others, it can be staked for yield.

One company has already built a $368 million BNB treasury, running validator nodes and staking positions that could generate millions annually.

Yet the market hasn’t priced it in.

This is the same model that turned MicroStrategy into a $95 billion Bitcoin titan. Only this time, the asset is stronger.

Click here to see the full opportunity before Wall Street wakes up.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

AutoZone (NYSE: AZO) is one of those companies that stays busy no matter what. People can skip fancy dinners, but they can’t ignore a dead battery.

That built-in demand is what keeps AutoZone cruising year after year.

The stock cooled off recently after a strong run, and at first glance, you might think something broke down. But this looks less like a blowout and more like a quick pit stop.

AutoZone is still opening stores, stacking shelves, and spending big on buybacks that quietly boost the value of every share.

Growth Now, Gas Later

Here’s the trade: AutoZone is plowing cash into expansion, which dents margins in the short term but builds muscle for the long haul.

It’s like paying for an engine upgrade today so you can hit higher speeds tomorrow.

Buybacks add extra fuel to the story. By reducing the share count, AutoZone keeps making every remaining slice of the pie a little bigger.

It’s not flashy, but it’s the kind of steady move that pays off when the road gets rough.

Is This Dip a Red Light or a Green One?

If you’re sizing up the pullback, the question is simple: is it a problem or a chance to get in cheaper? Some people will see cracks in the windshield.

Others will see a stock with plenty of gas in the tank waiting to accelerate.

AutoZone’s track record says it knows how to drive through bumps, and this pause could be the best moment to buckle in before the next stretch of open highway.

👉 Click here to get our closing report to your cell for free!

UniQure N.V. [QURE] $47.50 (+247.73%)

UniQure rocketed nearly 250% after its gene therapy AMT-130 showed a 75% slowing of Huntington’s disease progression in a Phase 1/2 study, hailed as “game-changing” by experts.

SHF Holdings Inc [SHFS] $7.27 (+123.01%)

SHF Holdings doubled after announcing a $150 million stock purchase agreement with CREO Investments, fueling optimism over capital strength and future growth.

Lithium Americas Corp [LAC] $6.00 (+95.52%)

Lithium Americas surged after reports that the U.S. government may take a 10% equity stake in its Nevada lithium mine as part of a $2.3 billion loan deal.

Fitell Corp [FTEL] $6.65 (-21.39%)

Fitell slid as enthusiasm around its $100M Solana treasury plan was overshadowed by Solana’s 10% weekly drop, raising concerns about exposure to crypto volatility.

Freeport- McMoRan Inc [FCX] $37.67 (-16.95%)

Freeport-McMoRan dropped after warning of weaker copper and gold sales due to a deadly mine accident in Indonesia that will keep production offline into 2026.

Harmony Biosciences Holdings Inc [HRMY] $26.72 (-16.70%)

Harmony plunged after its Phase 3 trial for ZYN002 in Fragile X syndrome failed to meet the primary endpoint, dampening hopes for approval.

This brand's not Nike-and that's the point.

It's fast, tech-driven, and built for viral drops.

Now, it has equity backing from one of college sports' most iconic names.

Find out why Bama is betting on this company

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.